Citations

Clear

382 citation(s) found for "Li, Man".

Radial Head Lag: A Possible Biomechanical Mechanism for Osteochondritis Dissecans of the Capitellum in Baseball Pitchers
Rotman, Dani , Liévano, Jorge Rojas , Hooke, Alexander W. , O’Driscoll, Shawn W. , Kwak, Jae-Man, Rojas Lievano, Jorge, Hooke, Alexander, Fitzsimmons, James S. , O'Driscoll, Shawn W., Fitzsimmons, James S , Kwak, Jae‐Man , Camp, Christopher L. , Lievano, Jorge Rojas

Mayo Clinic

The American Journal of Sports Medicine | September 15, 2021 | Volume: 49 | Issue: 12 | Pages: 3226-3233

10.1177/03635465211033971 | PMID 34523371 Get It

Background: Osteochondritis dissecans (OCD) of the capitellum is common in throwing athletes and is believed to result from repetitive overloading on the radiocapitellar (RC) joint, although the cause and mechanism remain unclear. The torsional forces (moments) generated by the triceps during elbow extension pull only on the ulna; therefore, the radial head moves passively across the capitellum and is effectively “dragged along” by the ulna. Any laxity in the proximal radioulnar joint could lead to asynchronous motion between the radius and ulna, resulting in the radial head lagging behind the coronoid and possibly malarticulating with the capitellum during such motion. Hypothesis: Radial head motion on the capitellum lags behind ulnohumeral joint motion during simulated throwing. Study Design: Controlled laboratory study. Methods: A total of 8 cadaveric elbows were tested under simulated throwing, including active extension of the elbow generated by pulling of the triceps under valgus stress, as well as during passive extension under valgus stress to serve as a reference. Ulnohumeral motion was tracked using a video camera. Radial head motion was tracked using an intra-articular, thin-film pressure sensor mounted on the capitellum, and the longitudinal movement of the center of force (COF) of the radial head was measured. Radial head motion was compared between passive and active motion for each 10° of elbow extension from 90° to 20°. Results: Elbow motion during simulated active extension reached an angular velocity of 366 deg/s. Radial head motion during simulated active extension significantly lagged compared with its motion during passive extension at every elbow extension angle examined between 70° and 20° ( P < .001). The maximal lag reached a mean of 4 mm (range, 2-7 mm). In other words, RC and ulnohumeral motion were asynchronous during simulated throwing. Conclusion: This study describes a novel phenomenon: motion of the radial head across the capitellum during rapid extension, such as in baseball pitching, lags behind that seen during passive elbow motion. According to a new proposed theory of OCD lesion development, this lag should result in RC incongruency and elevated shear forces on the capitellum due to edge loading. Clinical Relevance: We propose a new biomechanical explanation for OCD of the capitellum in baseball pitchers: radial head lag. Understanding this process is the first step in efforts to prevent this common injury.
Assessing the rate, natural history, and treatment trends of intracranial aneurysms in patients with intracranial dural arteriovenous fistulas: a Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) investigation
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R. , Sheehan, Jason P. , Gross, Bradley A. , Lockerman, Ashley, Brinjikji, Waleed , Starke, Robert M. , Chen, Stephanie H. , Potgieser, Adriaan R. E., Dijk, J. Marc C. van , Durnford, Andrew , Bulters, Diederik , Satomi, Junichiro, Tada, Yoshiteru , Kwasnicki, Amanda , Amin‐Hanjani, Sepideh , Alaraj, Ali , Hayakawa, M. , Derdeyn, Colin P. , Winkler, Ethan A. , Abla, Adib A. , Guniganti, Ridhima , Kansagra, Akash P. , Zipfel, Gregory J. , Kim, Louis J. , _, _, _, _, Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J., Patibandla, Mohana Rao, Buell, Thomas J. , Paisan, Gabriella, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Millar, John S. , Macdonald, Jason, Polifka, Adam , Laurent, Dimitri , Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Sur, Samir , Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Lawton, Michael T. , Rutkowski, Martin J. , Aziz‐Sultan, Mohammad Ali , Patel, Nirav , Frerichs, Kai U., Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching‐Jen , Gross, Bradley , Fox, W Christopher , Lanzino, Giuseppe , Samaniego, Edgar A , Lai, Pui Man Rosalind , Du, Rose , Kim, Louis J. , _, _, _, _, Raman, Hari S. , Lipsey, Kim L. , Giordan, Enrico , Link, Michael J. , Ding, Dale , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki , Phelps, Ryan

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 971-980

10.3171/2021.1.jns202861 | PMID 34507300 Get It

OBJECTIVE There is a reported elevated risk of cerebral aneurysms in patients with intracranial dural arteriovenous fistulas (dAVFs). However, the natural history, rate of spontaneous regression, and ideal treatment regimen are not well characterized. In this study, the authors aimed to describe the characteristics of patients with dAVFs and intracranial aneurysms and propose a classification system. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) database from 12 centers was retrospectively reviewed. Analysis was performed to compare dAVF patients with (dAVF+ cohort) and without (dAVF-only cohort) concomitant aneurysm. Aneurysms were categorized based on location as a dAVF flow-related aneurysm (FRA) or a dAVF non–flow-related aneurysm (NFRA), with further classification as extra- or intradural. Patients with traumatic pseudoaneurysms or aneurysms with associated arteriovenous malformations were excluded from the analysis. Patient demographics, dAVF anatomical information, aneurysm information, and follow-up data were collected. RESULTS Of the 1077 patients, 1043 were eligible for inclusion, comprising 978 (93.8%) and 65 (6.2%) in the dAVF-only and dAVF+ cohorts, respectively. There were 96 aneurysms in the dAVF+ cohort; 10 patients (1%) harbored 12 FRAs, and 55 patients (5.3%) harbored 84 NFRAs. Dural AVF+ patients had higher rates of smoking (59.3% vs 35.2%, p < 0.001) and illicit drug use (5.8% vs 1.5%, p = 0.02). Sixteen dAVF+ patients (24.6%) presented with aneurysm rupture, which represented 16.7% of the total aneurysms. One patient (1.5%) had aneurysm rupture during follow-up. Patients with dAVF+ were more likely to have a dAVF located in nonconventional locations, less likely to have arterial supply to the dAVF from external carotid artery branches, and more likely to have supply from pial branches. Rates of cortical venous drainage and Borden type distributions were comparable between cohorts. A minority (12.5%) of aneurysms were FRAs. The majority of the aneurysms underwent treatment via either endovascular (36.5%) or microsurgical (15.6%) technique. A small proportion of aneurysms managed conservatively either with or without dAVF treatment spontaneously regressed (6.2%). CONCLUSIONS Patients with dAVF have a similar risk of harboring a concomitant intracranial aneurysm unrelated to the dAVF (5.3%) compared with the general population (approximately 2%–5%) and a rare risk (0.9%) of harboring an FRA. Only 50% of FRAs are intradural. Dural AVF+ patients have differences in dAVF angioarchitecture. A subset of dAVF+ patients harbor FRAs that may regress after dAVF treatment.
Dural arteriovenous fistulas without cortical venous drainage: presentation, treatment, and outcomes
Samaniego, Edgar A., Roa, Jorge A., Hayakawa, Minako, Chen, Ching-Jen, Sheehan, Jason P., Kim, Louis J., Abecassis, Isaac Josh, Levitt, Michael R., Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Starke, Robert M., Sur, Samir, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib, Winkler, Ethan, Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Derdeyn, Colin P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Samaniego, Edgar A., Roa, Jorge A., Hayakawa, Minako, Chen, Ching-Jen, Sheehan, Jason P., Kim, Louis J., Abecassis, Isaac Josh, Levitt, Michael R., Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Kwasnicki, Amanda, Starke, Robert M., Sur, Samir, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru, Winkler, Ethan, Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 942-950

10.3171/2021.1.jns202825 | PMID 34507278 Get It

OBJECTIVE Current evidence suggests that intracranial dural arteriovenous fistulas (dAVFs) without cortical venous drainage (CVD) have a benign clinical course. However, no large study has evaluated the safety and efficacy of current treatments and their impact over the natural history of dAVFs without CVD. METHODS The authors conducted an analysis of the retrospectively collected multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) database. Patient demographics and presenting symptoms, angiographic features of the dAVFs, and treatment outcomes of patients with Borden type I dAVFs were reviewed. Clinical and radiological follow-up information was assessed to determine rates of new intracranial hemorrhage (ICH) or nonhemorrhagic neurological deficit (NHND), worsening of venous hyperdynamic symptoms (VHSs), angiographic recurrence, and progression or spontaneous regression of dAVFs over time. RESULTS A total of 342 patients/Borden type I dAVFs were identified. The mean patient age was 58.1 ± 15.6 years, and 62% were women. The mean follow-up time was 37.7 ± 54.3 months. Of 230 (67.3%) treated dAVFs, 178 (77%) underwent mainly endovascular embolization, 11 (4.7%) radiosurgery alone, and 4 (1.7%) open surgery as the primary modality. After the first embolization, most dAVFs (47.2%) achieved only partial reduction in early venous filling. Multiple complementary interventions increased complete obliteration rates from 37.9% after first embolization to 46.7% after two or more embolizations, and 55.2% after combined radiosurgery and open surgery. Immediate postprocedural complications occurred in 35 dAVFs (15.2%) and 6 (2.6%) with permanent sequelae. Of 127 completely obliterated dAVFs by any therapeutic modality, 2 (1.6%) showed angiographic recurrence/recanalization at a mean of 34.2 months after treatment. Progression to Borden-Shucart type II or III was documented in 2.2% of patients and subsequent development of a new dAVF in 1.6%. Partial spontaneous regression was found in 22 (21.4%) of 103 nontreated dAVFs. Multivariate Cox regression analysis demonstrated that older age, NHND, or severe venous-hyperdynamic symptoms at presentation and infratentorial location were associated with worse prognosis. Kaplan-Meier curves showed no significant difference for stable/improved symptoms survival probability in treated versus nontreated dAVFs. However, estimated survival times showed better trends for treated dAVFs compared with nontreated dAVFs (288.1 months vs 151.1 months, log-rank p = 0.28). This difference was statistically significant for treated dAVFs with 100% occlusion (394 months, log-rank p < 0.001). CONCLUSIONS Current therapeutic modalities for management of dAVFs without CVD may provide better symptom control when complete angiographic occlusion is achieved.
Intervention for unruptured high-grade intracranial dural arteriovenous fistulas: a multicenter study
Chen, Ching-Jen, Buell, Thomas J., Ding, Dale, Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Giordan, Enrico, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Sur, Samir, Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib A., Winkler, Ethan A., Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Sheehan, Jason P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Ding, Dale , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Ding, Dale , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Chen, Ching-Jen, Buell, Thomas J., Ding, Dale, Guniganti, Ridhima, Kansagra, Akash P., Lanzino, Giuseppe, Kim, Louis J., Abecassis, Isaac Josh, Bulters, Diederik, Durnford, Andrew, Fox, W. Christopher, Polifka, Adam J., Gross, Bradley A., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Alaraj, Ali, Kwasnicki, Amanda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Sur, Samir, Satomi, Junichiro, Tada, Yoshiteru, Abla, Adib A., Winkler, Ethan A., Du, Rose, Lai, Pui Man Rosalind, Zipfel, Gregory J., Sheehan, Jason P., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 962-970

10.3171/2021.1.jns202799 | PMID 34608140 Get It

OBJECTIVE The risk-to-benefit profile of treating an unruptured high-grade dural arteriovenous fistula (dAVF) is not clearly defined. The aim of this multicenter retrospective cohort study was to compare the outcomes of different interventions with observation for unruptured high-grade dAVFs. METHODS The authors retrospectively reviewed dAVF patients from 12 institutions participating in the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR). Patients with unruptured high-grade (Borden type II or III) dAVFs were included and categorized into four groups (observation, embolization, surgery, and stereotactic radiosurgery [SRS]) based on the initial management. The primary outcome was defined as the modified Rankin Scale (mRS) score at final follow-up. Secondary outcomes were good outcome (mRS scores 0–2) at final follow-up, symptomatic improvement, all-cause mortality, and dAVF obliteration. The outcomes of each intervention group were compared against those of the observation group as a reference, with adjustment for differences in baseline characteristics. RESULTS The study included 415 dAVF patients, accounting for 29, 324, 43, and 19 in the observation, embolization, surgery, and SRS groups, respectively. The mean radiological and clinical follow-up durations were 21 and 25 months, respectively. Functional outcomes were similar for embolization, surgery, and SRS compared with observation. With observation as a reference, obliteration rates were higher after embolization (adjusted OR [aOR] 7.147, p = 0.010) and surgery (aOR 33.803, p < 0.001) and all-cause mortality was lower after embolization (imputed, aOR 0.171, p = 0.040). Hemorrhage rates per 1000 patient-years were 101 for observation versus 9, 22, and 0 for embolization (p = 0.022), surgery (p = 0.245), and SRS (p = 0.077), respectively. Nonhemorrhagic neurological deficit rates were similar between each intervention group versus observation. CONCLUSIONS Embolization and surgery for unruptured high-grade dAVFs afforded a greater likelihood of obliteration than did observation. Embolization also reduced the risk of death and dAVF-associated hemorrhage compared with conservative management over a modest follow-up period. These findings support embolization as the first-line treatment of choice for appropriately selected unruptured Borden type II and III dAVFs.
Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR): rationale, design, and initial characterization of patient cohort
Guniganti, Ridhima, Giordan, Enrico, Chen, Ching-Jen, Abecassis, Isaac Josh, Levitt, Michael R., Durnford, Andrew, Smith, Jessica, Samaniego, Edgar A., Derdeyn, Colin P., Kwasnicki, Amanda, Alaraj, Ali, Potgieser, Adriaan R. E., Sur, Samir, Chen, Stephanie H., Tada, Yoshiteru, Winkler, Ethan, Phelps, Ryan R. L., Lai, Pui Man Rosalind, Du, Rose, Abla, Adib, Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van, Amin-Hanjani, Sepideh, Hayakawa, Minako, Gross, Bradley A., Fox, W. Christopher, Bulters, Diederik, Kim, Louis J., Sheehan, Jason, Lanzino, Giuseppe, Piccirillo, Jay F., Kansagra, Akash P., Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Smith, Jessica , Korai, Masaaki , Lai, Pui Man Rosalind , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Lai, Rosalind , Bulters, Diederik O , Derdeyn, Colin P , Guniganti, Ridhima, Giordan, Enrico, Chen, Ching-Jen, Abecassis, Isaac Josh, Levitt, Michael R., Durnford, Andrew, Smith, Jessica, Samaniego, Edgar A., Kwasnicki, Amanda, Alaraj, Ali, Potgieser, Adriaan R. E., Sur, Samir, Chen, Stephanie H., Tada, Yoshiteru, Winkler, Ethan, Phelps, Ryan R. L., Lai, Pui Man Rosalind, Du, Rose, Abla, Adib, Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van, Hayakawa, Minako, Gross, Bradley A., Fox, W. Christopher, Kim, Louis J., Sheehan, Jason, Lanzino, Giuseppe, Piccirillo, Jay F., Kansagra, Akash P., Zipfel, Gregory J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 951-961

10.3171/2021.1.jns202790 | PMID 34507282 Get It

OBJECTIVE Cranial dural arteriovenous fistulas (dAVFs) are rare lesions, hampering efforts to understand them and improve their care. To address this challenge, investigators with an established record of dAVF investigation formed an international, multicenter consortium aimed at better elucidating dAVF pathophysiology, imaging characteristics, natural history, and patient outcomes. This report describes the design of the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) and includes characterization of the 1077-patient cohort. METHODS Potential collaborators with established interest in the field were identified via systematic review of the literature. To ensure uniformity of data collection, a quality control process was instituted. Data were retrospectively obtained. RESULTS CONDOR comprises 14 centers in the United States, the United Kingdom, the Netherlands, and Japan that have pooled their data from 1077 dAVF patients seen between 1990 and 2017. The cohort includes 359 patients (33%) with Borden type I dAVFs, 175 (16%) with Borden type II fistulas, and 529 (49%) with Borden type III fistulas. Overall, 852 patients (79%) presented with fistula-related symptoms: 427 (40%) presented with nonaggressive symptoms such as tinnitus or orbital phenomena, 258 (24%) presented with intracranial hemorrhage, and 167 (16%) presented with nonhemorrhagic neurological deficits. A smaller proportion (224 patients, 21%), whose dAVFs were discovered incidentally, were asymptomatic. Many patients (85%, 911/1077) underwent treatment via endovascular embolization (55%, 587/1077), surgery (10%, 103/1077), radiosurgery (3%, 36/1077), or multimodal therapy (17%, 184/1077). The overall angiographic cure rate was 83% (758/911 treated), and treatment-related permanent neurological morbidity was 2% (27/1467 total procedures). The median time from diagnosis to follow-up was 380 days (IQR 120–1038.5 days). CONCLUSIONS With more than 1000 patients, the CONDOR registry represents the largest registry of cranial dAVF patient data in the world. These unique, well-annotated data will enable multiple future analyses to be performed to better understand dAVFs and their management.
Recurrence after cure in cranial dural arteriovenous fistulas: a collaborative effort by the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR)
Abecassis, Isaac Josh, Meyer, R. Michael, Levitt, Michael R., Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Bulters, Diederik, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Amin-Hanjani, Sepideh, Alaraj, Ali, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Abla, Adib, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Giordan, Enrico, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Derdeyn, Colin P., Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Korai, Masaaki, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Aziz-Sultan, M. Ali, Patel, Nirav, Frerichs, Kai U., Derdeyn, Colin P. , Amin‐Hanjani, Sepideh , Bulters, Diederik , Aziz‐Sultan, Mohammad Ali , Giordan, Enrico , Levitt, Michael R. , Hayakawa, M. , Alaraj, Ali , Dijk, J. Marc C. van , Abla, Adib A. , Korai, Masaaki , Levitt, Michael R , Amin-Hanjani, Sepideh , Alaraj, Ali , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Derdeyn, Colin P , Abecassis, Isaac Josh, Meyer, R. Michael, Sheehan, Jason P., Chen, Ching-Jen, Gross, Bradley A., Smith, Jessica, Fox, W. Christopher, Giordan, Enrico, Lanzino, Giuseppe, Starke, Robert M., Sur, Samir, Potgieser, Adriaan R. E., Dijk, J. Marc C. van, Durnford, Andrew, Satomi, Junichiro, Tada, Yoshiteru, Kwasnicki, Amanda, Samaniego, Edgar A., Hayakawa, Minako, Derdeyn, Colin P., Winkler, Ethan, Lai, Pui Man Rosalind, Du, Rose, Guniganti, Ridhima, Kansagra, Akash P., Zipfel, Gregory J., Kim, Louis J., _, _, _, _, Zipfel, Gregory J., Kansagra, Akash P., Guniganti, Ridhima, Piccirillo, Jay F., Raman, Hari, Lipsey, Kim, Lanzino, Giuseppe, Brinjikji, Waleed, Vine, Roanna, Cloft, Harry J., Kallmes, David F., Pollock, Bruce E., Link, Michael J., Sheehan, Jason, Chen, Ching-Jen, Patibandla, Mohana Rao, Ding, Dale, Buell, Thomas, Paisan, Gabriella, Kim, Louis J., Levitt, Michael R., Abecassis, Isaac Josh, Meyer, R. Michael, Kelly, Cory, Bulters, Diederik, Durnford, Andrew, Duffill, Jonathan, Ditchfield, Adam, Millar, John, Macdonald, Jason, Fox, W. Christopher, Polifka, Adam J., Laurent, Dimitri, Hoh, Brian, Smith, Jessica, Lockerman, Ashley, Gross, Bradley A., Lunsford, L. Dade, Jankowitz, Brian T., Hayakawa, Minako, Samaniego, Edgar A., Gutierrez, Santiago Ortega, Hasan, David, Roa, Jorge A., Rossen, James, Guerrero, Waldo, McGruder, Allen, Amin-Hanjani, Sepideh, Alaraj, Ali, Kwasnicki, Amanda, Charbel, Fady T., Aletich, Victor A., Rose-Finnell, Linda, Dijk, J. Marc C. van, Potgieser, Adriaan R. E., Starke, Robert M., Peterson, Eric C., Yavagal, Dileep R., Sur, Samir, Chen, Stephanie H., Satomi, Junichiro, Tada, Yoshiteru, Kanematsu, Yasuhisa, Yamamoto, Nobuaki, Kinouchi, Tomoya, Yamaguchi, Izumi, Yamamoto, Yuki, Abla, Adib, Winkler, Ethan, Phelps, Ryan R. L., Lawton, Michael, Rutkowski, Martin, Du, Rose, Lai, Pui Man Rosalind, Patel, Nirav, Frerichs, Kai U.

Mayo Clinic

Journal of Neurosurgery | September 10, 2021 | Volume: 136 | Issue: 4 | Pages: 981-989

10.3171/2021.1.jns202033 | PMID 34507283 Get It

OBJECTIVE Cranial dural arteriovenous fistulas (dAVFs) are often treated with endovascular therapy, but occasionally a multimodality approach including surgery and/or radiosurgery is utilized. Recurrence after an initial angiographic cure has been reported, with estimated rates ranging from 2% to 14.3%, but few risk factors have been identified. The objective of this study was to identify risk factors associated with recurrence of dAVF after putative cure. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) data were retrospectively reviewed. All patients with angiographic cure after treatment and subsequent angiographic follow-up were included. The primary outcome was recurrence, with risk factor analysis. Secondary outcomes included clinical outcomes, morbidity, and mortality associated with recurrence. Risk factor analysis was performed comparing the group of patients who experienced recurrence with those with durable cure (regardless of multiple recurrences). Time-to-event analysis was performed using all collective recurrence events (multiple per patients in some cases). RESULTS Of the 1077 patients included in the primary CONDOR data set, 457 met inclusion criteria. A total of 32 patients (7%) experienced 34 events of recurrence at a mean of 368.7 days (median 192 days). The recurrence rate was 4.5% overall. Kaplan-Meier analysis predicted long-term recurrence rates approaching 11% at 3 years. Grade III dAVFs treated with endovascular therapy were statistically significantly more likely to experience recurrence than those treated surgically (13.3% vs 0%, p = 0.0001). Tentorial location, cortical venous drainage, and deep cerebral venous drainage were all risk factors for recurrence. Endovascular intervention and radiosurgery were associated with recurrence. Six recurrences were symptomatic, including 2 with hemorrhage, 3 with nonhemorrhagic neurological deficit, and 1 with progressive flow-related symptoms (decreased vision). CONCLUSIONS Recurrence of dAVFs after putative cure can occur after endovascular treatment. Risk factors include tentorial location, cortical venous drainage, and deep cerebral drainage. Multimodality therapy can be used to achieve cure after recurrence. A delayed long-term angiographic evaluation (at least 1 year from cure) may be warranted, especially in cases with risk factors for recurrence.
Initiation of Gender-Affirming Testosterone Therapy in a Lactating Transgender Man
Oberhelman, Sara S. , Chang, Alice Y. , González, César A. , Braith, Andrew, Lteif, Aida, Oberhelman, Sara , Chang, Alice, Gonzalez, Cesar, Gonzalez, Cesar , Singh, Ravinder J.

Mayo Clinic

Journal of Human Lactation | September 7, 2021 | Volume: 38 | Issue: 2 | Pages: 339-343

10.1177/08903344211037646 | PMID 34490813 Get It

Introduction: Transgender and gender diverse individuals may choose to provide their infants with human milk. Lactating transgender men may experience gender dysphoria and desire to initiate or reinitiate gender-affirming testosterone therapy. However, there is limited safety data regarding use of testosterone during lactation. Main Issue: A 30-year-old G2P2 transgender man with gender dysphoria sought to initiate gender-affirming testosterone therapy while lactating. Management: Subcutaneous testosterone was self-administered beginning at 13 months post-partum. We prospectively collected data on circulating testosterone concentrations in parent serum, milk, and infant serum over 5 months until the infant self-weaned. The infant was monitored for growth and development at routine pediatric outpatient appointments. Parent serum testosterone concentrations rose with the initiation of testosterone therapy, reaching therapeutic concentrations by Day 14. Milk testosterone concentrations also increased with a maximum concentration of 35.9 ng/dl when the lactating parent was on a dose of 80 mg subcutaneous testosterone cypionate weekly. The calculated milk/plasma ratio remained under 1.0 and the calculated relative infant dose remained under 1%. The infant had no observable side effects, and his serum testosterone concentrations remained undetectable throughout the study period. Conclusion: This is the first study with data regarding human milk and infant serum testosterone concentrations during the initiation of gender-affirming testosterone therapy in a lactating individual. This evidence can help families and clinicians with decisions regarding lactation and testosterone use.
Genetics and Antiepileptic Mood Stabilizer Treatment Response in Bipolar Disorder: What do we Know?
Ho, Ada Man‐Choi , Weinshilboum, Richard M. , Frye, Mark A. , Biernacka, Joanna M. , Ho, Ada M-C , Biernacka, Joanna , Weinshilboum, Richard M.

Mayo Clinic

Pharmacogenomics | September 6, 2021 | Volume: 22 | Issue: 14 | Pages: 913-925

10.2217/pgs-2021-0041 | PMID 34486896 Get It

Gigantic retroperitoneal metastatic seminoma encasing the aorta in a young man
Wahab, Abdul, Hayat, Muhammad Hashim , Yousaf, Amman , Tariq, Raseen , Tariq, Raseen

Mayo Clinic

BMJ Case Reports | August 23, 2021 | Volume: 14 | Issue: 8 | Pages: e243190

10.1136/bcr-2021-243190 | PMID 34426421 Get It